Shionogi & Co., Ltd. Monday announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for FETROJA ® (cefiderocol) for the treatment of patients 18 years of age or older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by the following susceptible Gram-negative microorganisms: Acinetobacter baumannii complex, Escherichia coli, Enterobacter cloacae complex, Klebsiella pneumoniae, Pseudomonas aeruginosa and Serratia marcescens.
“Antimicrobial resistance is a major global health concern, and there is a clear need for new treatments such as FETROJA to give clinicians more options to fight life-threatening infections caused by Gram-negative pathogens,” said Akira Kato, Ph.D., president and CEO at Shionogi Inc. “This milestone represents Shionogi’s long-standing and unwavering commitment to constantly fight evolving infectious diseases in an era realizing significant unmet needs.”
This expanded indication is based on the results of the Phase III APEKS-NP study, which showed FETROJA met the primary endpoint of non-inferiority compared to high-dose extended-infusion meropenem in all-cause mortality 14 days after initiation of study drug in the treatment of patients with HABP, VABP and healthcare-associated bacterial pneumonia (HCABP).
“Nosocomial pneumonia is one of the most common hospital-acquired infections and a rising number are caused by difficult-to-treat, multidrug-resistant pathogens, which can be a deadly threat for patients,” said APEKS-NP principal investigator Richard G. Wunderink, M.D., Northwestern University Feinberg School of Medicine. “The results from the APEKS-NP study show that cefiderocol is a much-needed additional option for the treatment of patients with HABP and VABP due to multidrug-resistant Gram-negative bacteria.”
FETROJA is currently approved for patients 18 years of age or older for the treatment of complicated urinary tract infections, including pyelonephritis, caused by Gram-negative pathogens. It is the first approved antibiotic that functions as a siderophore and has a novel mechanism for penetrating the outer cell membrane of Gram-negative pathogens including carbapenem-resistant strains.
- Naegleria fowleri: Lake Jackson, Texas issues a a disaster declaration after the brain-eating amoeba is detected in its water system
- Lyme disease: Texas A&M researcher receives award for work on diagnostic test
- Michigan Eastern Equine Encephalitis: One human case, 32 animals
- COVID-19 vaccine data: strong immune response induced, protecting against infection, Clover Biopharmaceuticals announces
- Philippines nears 300K COVID-19 cases, Baguio to pilot rapid antigen testing
- Acanthamoeba acquired via contaminated soil while potting plants: NEJM
- Antibodies protect against wide range of influenza B virus strains